Testosterone and type 2 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 3, 2010, Pages 247-256

  Grossmann, Mathis ^a   Gianatti, Emily J ^a   Zajac, Jeffrey D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Androgens; Metabolic syndrome; Testosterone; Type 2 diabetes

Indexed keywords

CHORIONIC GONADOTROPIN; INSULIN; INSULIN SENSITIZING AGENT; OXANDROLONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

AGING; BODY FAT; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; EPIDEMIOLOGICAL DATA; EXERCISE; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; WEIGHT REDUCTION;

ADIPOSITY; AGING; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 77951849274     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833919cf     Document Type: Review

References (73)

1. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295:1288-1299.
2. Selvin E, Feinleib M, Zhang L. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30:234-238.
3. Grossmann M, Thomas MC, Panagiotopoulos S. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93:1834-1840.
4. Sikaris K, McLachlan RI, Kazlauskas R. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005; 90:5928-5936.
5. Kapoor D, Aldred H, Clark S. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30:911-917.
6. Dhindsa S, Prabhakar S, Sethi M. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89:5462-5468.
7. Laaksonen DE, Niskanen L, Punnonen K. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149:601-608.
8. Muller M, Grobbee DE, Den Tonkelaar I. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90:2618-2623. (Pubitemid 40686299)
9. Chubb SA, Hyde Z, Almeida OP. Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men study. Eur J Endocrinol 2008; 158:785-792.
10. Stellato RK, Feldman HA, Hamdy O. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23:490-494.
11. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25:55-60.
12. Laaksonen DE, Niskanen L, Punnonen K. Testosterone and sex hormonebinding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27:1036-1041.
13. Kupelian V, Page ST, Araujo AB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91:843-850.
14. Haring R, Volzke H, Felix SB. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009; 58:2027-2031.
15. Rajala UM, Keina SM, Hirsso PK. Associations of total testosterone and sex hormone-binding globulin levels with insulin sensitivity in middle-aged Finnish men. Diabetes Care 2007; 30:e13.
16. Endre T, Mattiasson I, Berglund G, Hulthen UL. Low testosterone and insulin resistance in hypertension-prone men. J Hum Hypertens 1996; 10:755-761.
17. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormonebinding globulin and body fat. Diabetes Care 2004; 27:861-868.
18. Ding EL, Song Y, Manson JE. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009; 361:1152-1163.
19. Nakhla AM, Leonard J, Hryb DJ, Rosner W. Sex hormone-binding globulin receptor signal transduction proceeds via a G protein. Steroids 1999; 64:213-216. (Pubitemid 29283674)
20. Hammes A, Andreassen TK, Spoelgen R. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122:751-762.
21. Pitteloud N, Mootha VK, Dwyer AA. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28:1636-1642.
22. Abate N, Haffner SM, Garg A. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002; 87:4522-4527.
23. Bojesen A, Kristensen K, Birkebaek NH. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 2006; 29:1591-1598.
24. Yialamas MA, Dwyer AA, Hanley E. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007; 92:4254-4259.
25. Laaksonen DE, Niskanen L, Punnonen K. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90:712-719.
26. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2:675-682.
27. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 2000; 24:485-491.
28. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14:247-254.
29. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24:4448-4456.
30. Isidori AM, Giannetta E, Greco EA. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a metaanalysis. Clin Endocrinol (Oxf) 2005; 63:280-293.
31. AllanCA, Strauss BJ, Burger HG. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008; 93:139-146.
32. Schroeder ET, Zheng L, Ong MD. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004; 89:4863-4872.
33. Marin P, Oden B, Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80:239-243.
34. Singh R, Artaza JN, Taylor WE. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144:5081-5088.
35. Singh R, Artaza JN, Taylor WE. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to downregulate adipogenic transcription factors. Endocrinology 2006; 147:141-154.
36. Xu XF, De Pergola G, Bjorntorp P. Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991; 128:379-382.
37. Malkin CJ, Pugh PJ, Jones RD. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89:3313-3318.
38. Corrales JJ, Almeida M, Burgo R. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigenpresenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 2006; 189:595-604.
39. Grillo ML, Jacobus AP, Scalco R. Testosterone rapidly stimulates insulin release from isolated pancreatic islets through a nongenomic dependent mechanism. Horm Metab Res 2005; 37:662-665.
40. Zitzmann M, Gromoll J, Nieschlag E. The androgen receptor CAG repeat polymorphism. Andrologia 2005; 37:216.
41. Hammoud A, Gibson M, Hunt SC. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab 2009; 94:1329-1332.
42. Niskanen L, Laaksonen DE, Punnonen K. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6:208-215.
43. Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Sex hormones and sexual function in obese men losing weight. Obes Res 2003; 11:689-694.
44. Pritchard J, Despres JP, Gagnon J. Plasma adrenal, gonadal, and conjugated steroids following long-term exercise-induced negative energy balance in identical twins. Metabolism 1999; 48:1120-1127.
45. Pritchard J, Despres JP, Gagnon J. Plasma adrenal, gonadal, and conjugated steroids before and after long-term overfeeding in identical twins. J Clin Endocrinol Metab 1998; 83:3277-3284.
46. Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003; 52:1126-1128.
47. Caprio M, Isidori AM, Carta AR. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 1999; 140:4939-4947.
48. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993; 76:1140-1146.
49. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009; 30:23-32.
50. Pitteloud N, Hardin M, Dwyer AA. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90:2636-2641.
51. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt - a major factor in the genesis of morbid obesity. Med Hypotheses 1999; 52:49-51.
52. Morley JE, Perry HM, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006; 20:424-429.
53. Grossmann M, Panagiotopolous S, Sharpe K. Low testosterone and anaemia in men with type 2 diabetes. Clin Endocrinol (Oxf) 2009; 70:547-553.
54. Marin P, Holmang S, Jonsson L. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16:991-997.
55. Marin P, Holmang S, Gustafsson C. Androgen treatment of abdominally obese men. Obes Res 1993; 1:245-251.
56. Liu PY, Wishart SM, Celermajer DS. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003; 148:55-66.
57. Page ST, Amory JK, Bowman FD. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90:1502-1510.
58. Basu R, Dalla Man C, Campioni M. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 2007; 30:1972-1978.
59. Svartberg J, Agledahl I, Figenschau Y. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008; 20:378-387.
60. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299:39-52.
61. Caminiti G, Volterrani M, Iellamo F. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54:919-927.
62. Bhasin S, Parker RA, Sattler F. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 2007; 92:1049-1057.
63. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6:1-7.
64. Corrales JJ, Burgo RM, Garca-Berrocal B. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004; 53:666-672.
65. Lee CH, Kuo SW, Hung YJ. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocr Res 2005; 31:139-148.
66. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154:899-906.
67. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30:726-733.
68. Gupal RA, Bothra N, Acharya SV. Treatment of hypogonadism with testosterone in type 2 diabetes mellitus. Endocr Pract 2010 [Epub ahead of print].
69. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24:313-340.
70. Woodhouse LJ, Gupta N, Bhasin M. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 2004; 89:718-726.
71. Singh AB, Hsia S, Alaupovic P. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87:136-143.
72. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91:4335-4343.
73. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992; 1:329-336